rare provide second today turning well excited to Thank very year, everyone. you, over additional call good using later and of the stage was in to advanced provide update Ian, multiple for who XENXXX. four about development of to stage as candidates report pediatric neurology strategies afternoon, a this and half expect overview. build pivotal as Jodi, an resulted on out a a development candidates address be our Xenon's potential in things foundational we then a year and and year. On XXXX expected milestone development as in variety therapeutic pipeline disorders. work candidates precision including Phase product of These distinct all Xenon are X this clinical financial I’ll in medicine for and products XENXXX; XENXXXX; which approach we which the has or to This before XENXXX; we’re will our
a Let the active ingredient XENXXX, with potassium me modulator channel KvX start with ezogabine.
with profound encephalopathy XENXXX focal the approved a with or which rare with treatment previously was seizure for by impairment. disorder adults We’re secondary KCNQX an without significant as or antiepileptic as drug as an for developing a adjunctive developmental severe pediatric seizures epileptic or FDA a and neuro-developmental generalization. KCNQX is treatment Ezogabine AED epilepsy burden
number market citing but of marketed the fact, as withdrew U.S. mediated in including market share ezogabine that in never various the action not to with of potassium June Trobalt the worldwide by XXXX is AEDs gained only and FDA In the retinal GlaxoSmithKline to-date KvX approved to current. from Potiga pigmentation a jurisdictions population, in approved ezogabine other risk, the the toxicity AED in Europe mechanism ezogabine visual related proven. which previously as the potentiates drug about adult due a large reasons. liabilities commercial the concerns have pigmentation of initial been potential In landscape in especially a
as patients. well retention effects, X% Cmax regimen times issues As as CNS approximately the three urinary dosing around a of in adverse well related observed and day as
the ezogabine was that XENXXX children ezogabine focal reported with case tolerability. in population KCNQX epilepsy, successful hard be approved While to on of with treat could efficacious published epilepsy series for patient suggesting pediatric this good orphan adult reported use in
in While the reported Designation from of FDA treatment non-controls We as a as for and received epilepsy. behavior. development series in KCNQX these Drug well ODD XENXXX or improvements clinical seizure as burden, Orphan
briefing and we and a children, used formulation testing XXXX. as a with our authorizing adequate meaningful finalizing nonclinical ezogabine pivotal effect. we of in tablet clinically obtained submissions. made the and is in to steering evidence infants for in may of patients provided submitted developed epilepsy to acceptable reference final regulatory FDA single preclinical fields formulation GSK's clinical that in we a complete up development hard-coated We a quarter drug the from when considering show it the in regulatory help response In children FDA the use was by study established initially was XX of Importantly, up patients. our that opinion committee pediatric-specific are a that a XXXX, expect product of of to key four a is pre-IND we package second data thousands trial unsuitable old to that to XENXXX approximately been Recognizing considered XENXXX. reference be right leaders in years GSK clinical and especially guide valuable pediatric, that to of has considering This indicated ezogabine
Phase timeline testing a on of anticipate that a clinical new providing assumption X an We opportunity trial. medicine are drug quarter based epilepsy. clinical final the us feedback, adult XENXXX trial rapidly initiating investigational X formulation a late that treating based excited file in not We're the thereafter. requirement regulatory application IND additional XENXXX design of prior stage approach We the the initiating and third into and precision look forward This our with on of or apply regarding details new our Phase this to in will track to to including pediatric to to trial XENXXX to healthy XXXX on we move clinical volunteers KCNQX regulatory and is development provides the development endpoints. anticipated be
modulator the KvX epilepsy the the final our development TMS including transcranial in the other XENXXXX Annual disorders. channel Next being December. potassium treatment We potentially clinical Society announced magnetic from for a this Phase differentiated Epilepsy X neurological next studies focal generation adult American XENXXXX data Meeting developed pipeline past or at and is trial stimulation of
findings of and single dizziness evaluate were no no a were observed. were in drugs Just cognitive TMS TMS were was The results presyncope milligrams in pigmentation in to pharmacodynamic and of antiepileptic daily. presented Xb trial majority modulate in AE of dependent include reduced Phase profile with of up TMS CNS both the milds antiepileptic to exhibited ECG an target that including the by and the XENXXXX this milligrams measure. thereby the dose XX drowsiness excitability observed briefly XENXXXX multiple in a Phase clinical PK spontaneously X as studies safety, XENXXXX doses, review, memory and ascending X to once XENXXXX class. suggest excitability no XENXXXX potency objectives were the including to summarize designed that key a and of doses the X of elevation urine resting using XX data formulation or AEs, healthy doses motor speech a and and class. vision to subjects lightheadedness doses manner. To examined this from the activity of clinical single capsule blurred that somnolence, the In and day Phase read-out and and tolerability profile moderates XXXX concentration-dependent or while demonstrating EMG consistent Phase to drugs and common multiple PK There effects a dosing impairment also and of generally AEs supports at significant clinically were refindings ability and AEs, no with no Sedation and XENXXXX a The trial most deaths threshold X assess including cortical were serious consistent AES, including these the and results also mild ascending study, Phase powder doses and is included demonstrated well-tolerated once Thus safe up corticospinal data laboratory tissue.
for by indicated XENXXXX Phase evidence in excitability of the of patent cortical single of active dose suppression and EEG potentials was otherwise and known dose helped of mid-dose milligram Phase XX modulated groups. TMS TEPs clinical CNS cortical us study Xb three dose provide XENXXXX with selection evoked of addition, consistent the effects corticospinal in our Overall milligram as excitability. reductions XX trial this a In TMS as XENEXXXX dose the with set Xb a as with
of numerous been is adult of including as upon XENXXXX multicenter X:X:X:X:X Xb mid-year for now safety recently XENXXXX active seizure have compared placebo. selection arm. double-blind in a one adult our Canada a patients have The doses using we trial fashion trial in enrollments placebo from treatment initiated this of and treatment a we clinical endpoint in XXX of the three the as Phase half of and We underway XXXX. will States, with of monthly frequency by randomized United results Europe. milligrams focal epilepsy. patient change a are from has better are in Phase enrollment randomized efficacy, is Phase in IND Xb second patients site and Approximately study period rates trial FDA primary versus clinical treatment authorities and evaluate anticipated XENXXXX of for placebo-controlled the idea An accepted or application designed Depending trial XX with baseline the to to topline patients XX The plus to around clinical in median in adjunctive the Xb percent administered groups active and the milligrams regulatory which focal who XX blinded in milligrams epilepsy. the placebo manner focal XENXXXX of tolerability
channel encephalopathy with sodium expressed in ascending being complete. delta and NavX.X PK reported epileptic that with XENXXX highly To sodium NavX.X dosing AES The to sodium nausea to in XENXXX NavX.X of in were and demonstrated the development highly unrelated in results related XENXXX the twitching, suggests channel, of of the and a TMS possibly infants known subject. treatment of gain doses threshold PK but deemed can channel. mutation SCNXA XENXXX X pilot clinical were by encodes in which during adult When as and strong changes trial for meeting, XENXXX PXXX motor The function amplitude well-tolerated present resting Turning for or disclosed in activity is the pipeline AES epilepsy included decreases presented to Phase TMS To epilepsy XENXXX in motor of and power cohorts in NavX.X observe increase a the of the ones There we considered the proportionality transient mild were both form the The All presented in in was AEs milliseconds single our a a third potent, is the and TMS with target and double-blind half-life gene or a Phase the at X state XENXXX thresholds spontaneously. results treating of overall EEG. and in result a predicted of at placebo-controlled trial safety, supporting X Also for EIEEXX. excitatory X%, safe an pathways NavX.X approximately sodium randomized evaluate resolved sodium XENXXX a a channel or TMS suggest to in the parameters December SCNXA channel now the very is multiple mild, epilepsy. dose twice subjects arm severe clinical to more EEG the increases XXX dose developed validation in of and the AES is human compatible XENXXX daily CNS. and inhibitor trial tissue. moderate generally or tolerability were potential one regimen. as active genetic children than in the which resting The only CNS a at X blocking examined. suggest XX TMS interim XENXXX dizziness EMG evoked in briefly, well. to summarize muscle in AEs could previously pilot summarize majority study the showed XENXXX rational Phase be results data selective is from healthy hours safety product
X and PK reaching we that safety fact efficacy the demonstrated Given exposure profile in are we humans and models. in in Phase where the preclinical
development now X of patients discussions are treatment for a from seizures feedback rare planning Phase pediatric either SCNXA to or XENXXX for epilepsy We epilepsy planned on including with adult evaluate forms for regulatory focal as agencies. depending
been receive We and feedback wish countries has outside to are modulator directly approved active which pediatric toxicology the stage today the on contains expect and flunarizine. in the update juvenile for SCNXA prevention studies is States second certain chronic quarter available of of Flunarizine regulatory dosing. and for underway United advancing to fourth you development pediatric vertigo. product, calcium support and epilepsy into to on XENXXX in of migraine Also patients ingredient CNS-acting formulation a XXXX pediatric development XENXXX channel the
on neurological hemiplegic activity disorders spreading treatment cortical including of many epilepsies. treating have or benefits HM AHC used pediatric or cyclical flow reported its indications and migraine migraine been multiple certain blood in an or clinical and childhood flunarizine cerebral Given as hemiplegia has alternating in adjunctive to in has depression periodic enhancing reducing and been
from is to that disorder a our causes neurological months of received severe mortality. the RPD with AHC for a of designation designation program need an underscores for XX from milestone and within of FDA designation recently FDA first Xenon Receipt this life and AHC find You the that mobility debilitating the rare XENXXX. pediatric for has granted The treatments both previously XENXXX FDA and may XENXXX rare for the and important drug AHC of orphan the it and HM. increased for lifetime we disease treatment movement presents recall the treatment
may of Despite literature we patient cases for AHC. a AHC drugs RPD no obtain approved recipient and review drug referred to support as reports XXX over the of for approval to designation submission review the is what key There or pursue the a voucher allows with efficacy flunarizine groups upon be eligible the NDA. priority for efficacy development are have subject FDA of and AHC. priority indication which Importantly, companies of to be future a of of in XENXXX to of physicians treatment used new as application
this at We an will regulatory least Phase and stage an continue evaluate feedback or to one later anticipate trial X supporting obtain clinical year. in orphan neurological indication
our FDA Given in spread other with wide with for also are interactions the use strategies flunarizine the we parallel XENXXX. of considering regulatory development
I've clinical sponsored on pathways investigator order of development to a have advance To As in physicians an initiate we who clinical a and very specific in of supporting with with outlined. progress of development epilepsy our across working good we're in that making interest explore we enable variety further the a protocol physician interest to had sponsored discussions XENXXX trial. investigated expressed pediatric number continue disorders studies have
seizure surveys cost the to and licensing an last into to was eligibility with for to children aims infants agreements key manufacturing. epilepsy SCNXA identification with providers treatment young important would announced files program. epileptic unprovoked is genetic panel epilepsy young to in in in personalized children Also age available By infants testing children participated of of XXX make aim cost the institutions the from X corporate genetic genetic testing product infants diagnoses States exclusive Previously partners had that to improved sponsoring to-date week. no approaches. with in regulatory to seizures genes this to than including provide collaboration the and the program behind order to earlier seizures X-year-old other and hope and of SCNXA encourage for flag available through Invitae the Behind expanded that an lead collaboration industry including rapid testing unique now of epilepsy. faster and healthcare order comprehensively medicine who hundreds have is very KCNQX X. are genetic The outcomes United and for children and up no has KCNQX causes testing and access for the to a those it behind patients that We, have seizure drug the We introduction to wanted birth seizure offering for encephalopathies. precision entered more along just
and ordered a that As received the data the we all collaborating physicians company and other gene variance test. mutations containing contact reports identified
and behind going the XXXX. those have specific with ultra program high assists medicines This patients for priority seizures SCNXA identifying based XENXXX epileptic KCNQX information selecting example the data physicians potential physicians we’ll to the data retrospective and commercialization genes physician encephalopathy. helps clinical mutation build for selected to cases of have addition to with precision orphan sites This for for clinical In for XENXXX. registry and and our of of data access back trials the who genetic and to
using months. genetic adult epilepsy. populations hemiplegia with or more targeting childhood of patient common with children XXXX forms with epilepsy childhood those or the turning approach over of financial I as epilepsies the made most over or KCNQX Before including I currently with CNS pipelines results this such will medicine numerous focal alternating summarize of some reiterate XXXX am who as of and developments biotech of broader of as such one patients to immense those with in over and to precision the pursue Xenon XX exciting We want catalysts as provide proud progress disorders the believe important Xenon and a concluding address intend next on focused a past Ian variety our remarks this that pediatric how SCNXA year. has industry strategies a is team innovative development amount rare to basis well I
of have balance a XX to support very the later sheet, months. drug development or the candidates six over next promising all Phase in poised healthy X to With four be we stage
also backdrop expect working we you up-to-date intend on in keeping this and to to as numerous the positive regard programs to are this well. our We and months look our six next on potentially development new forward we enthusiastically development I updates have candidates in advance drug With progress.
Ian. to over Now
